Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195057 | 0.88 | SLC6A4 (0.49) | SIRT6PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL137523 | 0.87 | SIRT6 (0.56) | TDP1ATMKCNMA1SIRT6PDGFRB | |
| SCHEMBL31548078 | 0.87 | SIRT6 (0.56) | TDP1ATMKCNMA1SIRT6PDGFRB | |
| SCHEMBL29938615 | 0.86 | TDP1 (0.47) | TDP1ATMKCNMA1LGALS3LGALS4 | |
| SCHEMBL28845796 | 0.85 | ALDH1A1 (0.45) | TDP1ATMLGALS3LGALS4SIRT6 | |
| SCHEMBL2151631 | 0.85 | TDP1 (0.46) | TDP1ATMKCNMA1LGALS3LGALS4 | |
| SCHEMBL5191949 | 0.84 | ABCB1 (0.48) | KCNMA1SIRT6ALDH1A1SLC6A4SLC6A3 | |
| SCHEMBL5192536 | 0.84 | ABCB1 (0.54) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL31391703 | 0.83 | MAPT (0.55) | TDP1ATMLGALS3LGALS4ALDH1A1 | |
| SCHEMBL3092769 | 0.83 | MAPT (0.55) | TDP1ATMLGALS3LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-111699176-B | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119285605-A | Quinazolinone-based LSD1 inhibitors | 河南中医药大学 | 2025-01-10 | — | — | CN | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| CN-114728910-B | Pyrazole derivative for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | US | disclosed |
| WO-2004054985-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-01 | — | — | WO | disclosed |
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| CN-1253545-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | TDP1 1423/4885ATM 2862/4885KCNMA1 3125/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | TDP1 120/4885ATM 722/4885KCNMA1 3465/4885 |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | TDP1 3293/4885ATM 4279/4885KCNMA1 4152/4885 |
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | TDP1 948/4885ATM 4278/4885KCNMA1 391/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | TDP1 1159/4885ATM 2584/4885KCNMA1 2263/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | TDP1 3099/4885ATM 4336/4885KCNMA1 4206/4885 |
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | MAOB, MAOA, COMT | TDP1 535/4885ATM 2493/4885KCNMA1 2913/4885 |
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | TDP1 377/4885ATM 262/4885KCNMA1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.